Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sarilumab Set To Clear EU Hurdle In RA But Actemra Specter Remains

Executive Summary

While Sanofi/Regeneron's sarilumab is set to be the first of the newer IL-6 products to be cleared for rheumatoid arthritis treatment in Europe and the US, its commercial success is under doubt with physicians trying anti-TNF treatments first, followed by Roche's established IL-6 drug Actemra (tocilizumab).

You may also be interested in...



28 New Drug Approvals In EU: Cancer Dominates, But RA, Skin & Blood Disorders Well Served Too

Twenty-eight new products containing a total of 29 new active substances were authorized for marketing in the EU in 2017, very much line with the 2016 tally. As in that year, oncology dominated the 2017 approvals, which also included new drugs for rheumatoid arthritis, skin & blood disorders, and hepatitis C.

28 New Drug Approvals In EU: Cancer Dominates, But RA, Skin & Blood Disorders Well Served Too

Twenty-eight new products containing a total of 29 new active substances were authorized for marketing in the EU in 2017, very much line with the 2016 tally. As in that year, oncology dominated the 2017 approvals, which also included new drugs for rheumatoid arthritis, skin & blood disorders, and hepatitis C.

Baricitinib Complete Response May Put Lilly/Incyte Behind IL-6 Blockers In RA

FDA complete response letter seeks additional data on dosing and other safety concerns, delaying potential approval for an NDA that already had been pushed back three months. Interleukin-6 inhibitors sarilumab and sirukumab, now under review at FDA, both could obtain approval before baricitinib.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1127945

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel